Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy

Yoon-Kyoung SUNG; Soo-Kyung CHO; Dam KIM; Soyoung WON; Chan-Bum CHOI; Tae-Hwan KIM; Jae-Bum JUN; Dae-Hyun YOO; Sang-Cheol BAE.
The Korean Journal of Internal Medicine ; : 1016-1024, 2018.
Artículo en Inglés | WPRIM | ID: wpr-717180

Documentos relacionados

  1. Current Status of Latent Tuberculosis Infection Treatment Among Pediatric Patients in Korea: Prescription and Treatment Completion.
  2. Treatment of latent tuberculosis infection in patients receiving biologic agents.
  3. Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study.
  4. Patient-Reported Barriers to Treatment Initiation and Completion for Latent Tuberculosis Infection Among Patients Within a Large Integrated Health Care System in Southern California.
  5. Ramadan and Culturally Competent Care: Strengthening Tuberculosis Protections for Recently Resettled Muslim Refugees.
  6. Simplifying Rifapentine Dosing for Tuberculosis Treatment and Prevention.
  7. No evidence of increased risk of acquired rifampin resistance.
  8. Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection.
  9. Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV.
  10. Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.